@entity2719 scans in the evaluation of residual masses after chemotherapy for XXXX .

@entity1 @entity39 @entity5 @entity2719 @entity3 @entity4797
PURPOSE: To assess the ability of @entity2719 scans to determine whether residual masses consist of viable @entity5 or @entity39 fibrous tissue after chemotherapy for @entity4797 . @entity1 AND METHODS: Thirty-two @entity1 were enrolled and 27 were assessable. @entity1 receiving first-line or salvage chemotherapy had @entity2719 scans performed during their first and last scheduled course of chemotherapy and results were compared with restaging computed tomographic (CT) scans and subsequent clinical outcome. RESULTS: Of 27 assessable @entity1 , 22 received first-line chemotherapy (group A) and five salvage chemotherapy (group B). Eight @entity1 were not @entity2719 -avid before chemotherapy despite obvious clinical and radiographic evidence of @entity3 . Eighteen of 19 @entity2719 -positive @entity1 had a persistent mass postchemotherapy on abdominal CT. Of 16 @entity1 in group A whose @entity5 were @entity2719 -avid, all 16 had normalized @entity2719 scans after chemotherapy. However, two of these 16 @entity1 recurred in their original disease site. In group B, there were three @entity1 with @entity2719 -avid @entity5 and all three had normalized scans postchemotherapy. Two @entity1 who were not @entity2719 -avid (one each in group A and B) also developed recurrent disease. Twenty-four of 27 @entity1 are alive with no evidence of active disease at a median follow-up time of 18 months, including 20 with more than 1 year of follow-up data. CONCLUSION: Eight of 27 @entity1 had false-negative @entity2719 scans at the time of diagnosis. All nineteen @entity2719 scans that were initially positive reverted to normal after chemotherapy. Two of 19 @entity1 ' follow-up @entity2719 scans were false-negative. We therefore feel that @entity2719 scans have minimal value in the prechemotherapy or postchemotherapy evaluation of @entity3 .
